Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001180 · ClinicalTrials.gov registry record

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

A clinical trial of Healthy and Cushing's Syndrome, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
2,250
Enrollment target
1
Study location

NCT00001180: Completed study of Healthy and Cushing's Syndrome, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

NCT00001180 is a study of Healthy and Cushing's Syndrome that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 2,250 participants, above the 645-participant average among 1,090 other Healthy trials with a reported enrollment target (249% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001180, a study of Healthy and Cushing's Syndrome, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
2,250 participants
Enrollment target
1
Study location

Study Summary

Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones. The order of amino acids in CRH, has been determined, meaning that the hormone can now be synthetically reproduced in a laboratory setting. When CRH is released from the hypothalamus it stimulates the pituitary gland to secrete another hormone, ACTH. ACTH then causes the adrenal glands to make a third hormone, cortisol. This process is known as the hypothalamic-pituitary-adrenal axis. Problems can occur in any of the steps of this process and result in a variety of diseases (Cushing's Syndrome and adrenal insufficiency). Researchers hope that CRH created in a laboratory setting, ovine CRH (oCRH) can be used to help diagnose and treat conditions of the HPA axis. This study will test the relationship for single doses of oCRH in normal volunteers and patients with disorders of the HPA axis. The oCRH will be injected into the patients vein as a single injection or slowly through an IV line over 24 hours. The participants will have blood tests taken to measure hormone levels before, during, and after receiving the oCRH.

Conditions Studied

Healthy Cushing's Syndrome Adrenal Gland Hyperfunction Adrenal Gland Hypofunction

Interventions

  • DRUG Ovine Corticotropin-Releasing Hormone (oCRH)

Study Locations (1)

Maryland

  • National Institute of Child Health and Human Development (NICHD) - Bethesda

Trial Details

FieldValue
Enrollment Target 2,250 participants
Start Date 1982-03
Est. Completion 2005-06
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

305 total trials

What the finished NCT00001180 record still lists

NCT00001180 is an observational study that tracks outcomes without assigning an intervention. Its 2,250 participants enrollment target places it among the larger protocols in the corpus, above the 645-participant average among 1,090 other Healthy trials with a reported enrollment target (249% higher).

The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Ovine Corticotropin-Releasing Hormone (oCRH) is the first listed.

NCT00001180 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00001180 about?

NCT00001180 is a clinical study titled "Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency". Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones. The order of amino acids in CRH, has been determined, meaning that the hormone can now be synthetically reproduced in a ...

What is the current status of trial NCT00001180?

This trial is currently completed. The enrollment target is 2,250 participants. The study started on 1982-03. Estimated completion is 2005-06.

What conditions does trial NCT00001180 study?

This clinical trial studies the following conditions: Healthy, Cushing's Syndrome, Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction.

What interventions are being tested in trial NCT00001180?

The interventions under investigation include: Ovine Corticotropin-Releasing Hormone (oCRH) (DRUG).

Who is sponsoring clinical trial NCT00001180?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001180 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001180's enrollment target sits among peer trials

2,250 21st of 1090 higher than 1,070 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04889872 · 2,250 participants · NA

    PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

  • NCT06805513 · 2,250 participants · Phase 3

    Actual Use Trial of Tadalafil 5 mg

  • NCT06939803 · 2,236 participants · NA

    AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

  • NCT06831929 · 2,232 participants · NA

    HPV Ends Here: Increasing Uptake of the HPV Vaccine

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00001180, the US trial registry maintained by the National Library of Medicine. NCT00001180 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.